Bioxodes’ Post

Twenty-two years since its formation, BioArctic expects to become profitable in 2025, as milestones for marketing approvals and royalties on sales of the Alzheimer’s drug #Leqembi (lecanemab) roll in, and partners sign up to use its proprietary #Braintransporter drug delivery technology. “Bioarctic is now entering a new era. It’s an era of profitable growth,” said Gunilla Osswald, CEO, presenting second-quarter results on Aug. 28. “It’s signified by a yet another strong quarter and a lot of activity throughout the different parts of the business,” she said. Read Nuala Moran's article in BioWorld News: https://lnkd.in/eDnz-Zjp #biopharma #Alzheimersdisease #neurodegeneration Clarivate for Life Sciences & Healthcare

The 𝘕𝘶𝘤𝘭𝘦𝘶𝘴 𝘕𝘢𝘷𝘪𝘨𝘢𝘵𝘰𝘳 has reached its final destination: North America.📍 From biotech startups to pharma leaders, the United States and Canada are home to a high concentration of RLT innovation. The region is defined by strong investment activity, established radiopharma infrastructure, and a deep bench of clinical and regulatory expertise. With every region now featured, each 𝘕𝘢𝘷𝘪𝘨𝘢𝘵𝘰𝘳 paints a clear picture: RLT is no longer a niche; it's a global movement that's scaling fast. Thank you for following along on our journey around the globe! Scroll back on our page to explore Australia, Asia, Europe, and the Middle East. To receive the interactive version with clickable links to product information, visit https://hubs.ly/Q03FQw8G0. #Radiopharmaceuticals #NucleusNavigator #ClinicalDevelopment #RLT #USBiotech #CanadaBiotech #Pluvicto #Lutathera #Xofigo

𝐃𝐢𝐝 𝐲𝐨𝐮 𝐤𝐧𝐨𝐰 𝐲𝐨𝐮 𝐝𝐨𝐧’𝐭 𝐧𝐞𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐛𝐚𝐬𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐄𝐔 𝐭𝐨 𝐛𝐞𝐧𝐞𝐟𝐢𝐭 𝐟𝐫𝐨𝐦 𝐒𝐌𝐄 𝐒𝐭𝐚𝐭𝐮𝐬 𝐨𝐫 𝐎𝐫𝐩𝐡𝐚𝐧 𝐃𝐫𝐮𝐠 𝐃𝐞𝐬𝐢𝐠𝐧𝐚𝐭𝐢𝐨𝐧? Too many companies miss out on these incentives, either because they don’t realise they’re eligible or find the application process too complex. 𝐓𝐡𝐞 𝐫𝐞𝐬𝐮𝐥𝐭? Lost time, higher costs, and missed opportunities to protect innovation. At tranScrip, we help biotech and pharma companies unlock cost savings, regulatory guidance, market exclusivity and accelerated pathways - ensuring you maximise value and bring medicines to patients faster. Discover how SME Status and ODD can transform your EU drug development strategy: https://lnkd.in/ecR5TT8q #OrphanDrug #SMEStatus #Biotech #DrugDevelopment 

CGT development is nothing if not complex. Inefficient processes. Complex analytics. An evolving regulatory landscape. Yet, patients are waiting for life-saving advanced therapies. Our team at TKD Solutions understands this and brings CGT problem-solving skills honed from our range of experiences at small biotech to big pharma to help solve your challenges in CGT development and get your therapy on a pathway to patients in need.   Learn more in our latest article: https://lnkd.in/g4wVZ-Vp   #TKDSolutions #Biotech #CellAndGeneTherapy #GeneTherapy #QbD #Biomanufacturing

Biotech momentum is real — and Q2 2025 proved it. ⬇️ From targeted therapies to smarter delivery systems, the #FDA cleared several first-in-class or best-in-class drugs this past quarter. But these weren’t just routine #approvals. They signal where innovation is going — and what regulators are ready to support. We put together a visual snapshot of 5 approvals that matter → #FDAApprovals #Biotech #DrugDevelopment #SymmetricTraining #2025

“Why Australia? Why Now?” At BIO 2025, BioCina’s CEO Mark W. Womack spoke with Pharma's Almanac to unpack the growing advantages of choosing Australia for clinical manufacturing and how BioCina’s integrated CDMO platform is leading the charge. In this conversation, Mark highlights: ·      How Australia’s R&D tax incentive (up to 48.5%) dramatically boosts ROI. ·      Why programs reach Phase I faster under Australia’s streamlined regulatory path. ·      How a connected biotech ecosystem and 11% share of global clinical trials give Australia an edge. ·      BioCina’s Adelaide and Perth sites are uniquely positioned for microbial biologics, pDNA, mRNA, and LNP programs, offering true end-to-end CDMO services. If you’re looking for speed, value, and global quality standards, this is a conversation worth watching. BIO International Convention | Benjamin McLeod #ThinkBioCina #GlobalCDMO #Innovation #GMPAustralia

Nice interview with BioCina's CEO Mark W. Womack at BIO 2025 talking about the advantages of biomanufacturing in Australia. BioCina has manufacturing facilities in both Perth and Adelaide.

I believe in this company's work and I endorse it. Thank you Jim Jenson and team. Some of the relevant work on aging, which I find quite useful and innovative is listed below. In terms of mental health, it resonates with the work by Frank Putnam and his colleagues on faster aging in individuals with complex PTSD, faster onset of puberty, higher obesity rates, etc. It also resonates with the epigenetic work at the Ludmer Centre at McGill University by Patricia Silveira and colleagues. https://lnkd.in/efgAcje6 Pio-Lopez, L., & Levin, M. (2024). Aging as a loss of morphostatic information: A developmental bioelectricity perspective. Ageing Research Reviews, 97, 102310. Pio-Lopez, L., & Levin, M. (2023). Morphoceuticals: Perspectives for discovery of drugs targeting anatomical control mechanisms in regenerative medicine, cancer and aging. Drug Discovery Today, 28(6), 103585. Oviedo, N. J., Nicolas, C. L., Adams, D. S., & Levin, M. (2008). Planarians: a versatile and powerful model system for molecular studies of regeneration, adult stem cell regulation, aging, and behavior. Cold Spring Harbor Protocols, 2008(10), pdb-emo101. #aging

The incorporation of oxygen atoms can reduce a molecule's logP (lipophilicity) by enhancing hydrophilicity, while also lowering the pKa of nearby basic groups to modulate their basicity. Explore our novel spiro- building blocks to advance your drug discovery programs. Author: Jin Li & Feng Xu Editor: Lisha Wang salesusa@pharmablock.com；product.pharmablock.com PharmaBlock Group; PharmaBlock (USA), Inc. #DrugDiscovery #Innovation #Biotech #HitIdentification #LeadOptimization #StrategicPartnership #Biotech #PharmaceuticalResearch #PharmaceuticalInnovation